Lianhuan Pharmaceuticals: Azithromycin raw materials medicine obtained approved for market application.

Lianhuan Pharmaceuticals Announcement: Recently, the company received the "Chemical Raw Material Drug Market Approval Notification" for the active pharmaceutical ingredient Agomelatine issued by the National Medical Products Administration. The status of this raw material drug on the CDE raw material package registration information platform is "A". According to the information on the National Medical Products Administration Drug Evaluation Center raw material package registration information platform, as of the disclosure date of this announcement, there are a total of 19 registered numbers for domestic Agomelatine raw material drugs, with 15 of them showing a status of "A". As of the disclosure date of this announcement, the company has accumulated research and development investment for Agomelatine raw material drugs of approximately RMB 3.6464 million.